Every Form 4 that Biomea Fusion, Inc. (BMEA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BMEA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMEA filings page.
Biomea Fusion, Inc. director Elizabeth Faust received a grant of stock options covering 196,299 shares of common stock at an exercise price of $1.15 per share. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, contingent on her continued service. Following this grant, she holds 196,299 derivative securities directly.
Biomea Fusion, Inc. director Eric Aguiar received a grant of stock options covering 196,299 shares of common stock. The options have an exercise price of $1.15 per share and expire on June 9, 2036.
The options were granted as compensation rather than an open-market purchase. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, provided Aguiar continues to serve the company through that vesting date.
Biomea Fusion, Inc. director Ray Sumita received a stock option grant covering 196,299 shares of common stock. The option has an exercise price of $1.1500 per share and expires on June 9, 2036. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, subject to Sumita’s continued service. Following this compensation-related award, Sumita holds 196,299 derivative securities directly, with no open-market buying or selling reported.
Biomea Fusion, Inc. director Julianne Averill reported receiving a stock option grant under the company’s equity plan. The option covers 173,711 shares of Common Stock at an exercise price of $1.15 per share and expires on June 9, 2036.
The filing states this is a compensation-related award, not an open-market purchase or sale. According to the vesting terms, all underlying shares will vest in full on the earlier of one year from the grant date or immediately before the next annual stockholder meeting, provided she continues serving the company through that date.
Biomea Fusion, Inc. director and officer Rainer M. Erdtmann received a grant of stock options covering 452,512 shares of common stock. The options have an exercise price of $1.49 per share and expire on March 31, 2036.
According to the terms, the award will vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested and exercisable on April 1, 2030, subject to his continued service with the company. Following this grant, he holds 452,512 derivative securities directly.
Biomea Fusion, Inc. reported that Interim CEO and director Michael J.M. Hitchcock received a grant of stock options covering 667,477 shares of Common Stock on April 1, 2026. The options have an exercise price of $1.49 per share and expire on March 31, 2036.
According to the terms, the option will vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested and exercisable on April 1, 2030, as long as Hitchcock continues to serve the company through each vesting date. Following this grant, he holds 667,477 derivative securities directly.
Biomea Fusion, Inc. executive and director Rainer M. Erdtmann reported buying 30,000 shares of Biomea Fusion common stock on 12/11/2025 at a weighted-average price of $1.4333 per share. After this transaction, he directly owns 723,027 shares.
Erdtmann also reports indirect holdings, including 19,400 shares held by a daughter, 20,000 shares held by a son, 20,000 shares held by another daughter, and additional shares held in two independent trusts and two Point Sur investment entities where he has voting or dispositive power but disclaims beneficial ownership beyond any pecuniary interest. He serves as President, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer, and a director of Biomea Fusion. The 30,000-share purchase was executed in multiple trades between $1.42 and $1.46 per share.